The tweet was deleted by the author.
But we saved everything 🙂.
Monte Rosa Therapeutics has presented preclinical data at AACR26 regarding its CCNE1-directed molecular glue degrader, aimed at treating CCNE1-amplified solid tumors.
The approach suggests a new potential pathway for targeting a historically undruggable cancer gene, which could open future research and therapeutic avenues. Full details were shared as part of the company’s scientific presentation at the event.
Monte Rosa Therapeutics has previously championed early engagement and expanded opportunities for scientists during Women’s History Month. CEO Markus Warmuth is set to join industry experts at AACR2026 to discuss proximity-induced therapies. The company continues to highlight its research focus at major scientific forums.